Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib with R-DHAP in Relapsed/Refractory DLBCL
NCT01805557Phase 3Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Feb 2013
- Primary completion
- Mar 2019
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of bortezomib in diffuse large B-cell lymphoma (DLBCL), sponsored by Fondazione Italiana Linfomi. Started Feb 2013; status: completed.
02
Drugs
bortezomib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01805557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01805557.